*: ITT population. †: One patient assigned to the placebo group received one dose of pertuzumab in error and was included in the safety population for the pertuzumab group; Final safety population: pertuzumab (n=385), placebo (n=388). ‡: These patients were enrolled in the study but ...
infusion related reactionspertuzumabPertuzumab is a monoclonal antibody that targets and down regulates HER-2/neu expression in ductal breast tumors. Other HER-2/neu monoclonal antibodies, particularly trastuzumab, have been implicated to induce infusion related reactions such as cytokine release syndrome...
除最初的Tz-PHF-vinca,XMT-1522也是利用该技术平台构建,平均DAR值为12,抗体与HER2的结合表位不同于Trastuzumab/Pertuzumab;在小鼠异种移植模型中具有较高的抗肿瘤作用(单剂量0.67 mg/kg),并且在对Tz-DM1不敏感的HER2+表达模型中可延长无瘤生存期(单剂量2 mg/kg),其治疗指数(TI) >40,这与其内化释放的AF-HPA...
To the EditorHuober and colleagues1conducted an important analysis of a randomized clinical trial to assess if it is reasonable for patients to receive first-line pertuzumab plus trastuzumab alone (group A) vs with chemotherapy (group B) followed by trastuzumab and emtansine after progression. The...
Dual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer. Wolfgang Janni, MD, PhD Treatment with the chemotherapy-sparing combination of trastuzumab (Herceptin) and pertuzumab (Perjeta) was tol...
for patients who are presenting with stage two or three HER2-positive breast cancer. It's given preoperatively along with chemotherapy then the patients go to surgery. If they're a pathologic complete response, then they can continue the trastuzumab and pertuzumab subcutaneously to finish up th...
Trastuzumab and pertuzumab in hemodialysis: A case report. PMID: 33779370Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer. PMID: 36259134Trastuzumab emtansine and cost-based decision making. PMID: 28091366Is weight-based IV dosing of trastuzumab preferable to SC ...
Huober J, Barrios CH, Niikura N, et al. Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): final results of the phase III IMpassion050 trial. Ann Oncol. 2024;9(suppl 4):1-25. doi:10.1016/esmoop/esmoop103096 ...
Pertuzumab联合trastuzumab和化疗一线治疗转移性HER2胃或胃食管交界癌(JACOB)研究解读 本期分享的是2018年9月11日发表在Lancet Oncol上的JACOB研究的最终分析。JACOB研究旨在比较帕妥珠单抗(pertuzumab)联合曲妥珠单抗(tratuzumab)和化疗对比tratuzumab和化疗一线治疗转移性HER2阳性的胃或胃食管交界癌患者,以探讨在目前trat...
Pertuzumab (a type of monoclonal antibody) Trastuzumab Deruxtecan (a type of HER2-directed antibody drug conjugate) Tucatinib (Tyrosine Kinase HER2 Inhibitor) Ado-trastuzumab emtansine or T-DM1 (a type of HER2-targeted antibody-drug conjugate) ...